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MINI-ABSTRACT 
This work examines the skeletal accumulation of fluorescently-tagged zoledronate in an animal 
model of chronic kidney disease. The results show higher accumulation 24-hours post-dose in 
animals with lower kidney function due to greater amounts of binding at individual surfaces. 
 
ABSTRACT 
Purpose/Introduction Chronic kidney disease (CKD) patients suffer from increased rates of 
skeletal related mortality from changes driven by biochemical abnormalities. Bisphosphonates 
are commonly used in reducing fracture risk in a variety of diseases yet, their use is not 
recommended in advanced stages of CKD. This study aimed to characterize the accumulation of 
a single dose of fluorescently-tagged zoledronate (FAM-ZOL) in the setting of reduced kidney 
function. Methods At 25 weeks of age, FAM-ZOL was administered to normal and CKD rats.  24-
hours later, multiple bones were collected and assessed using bulk fluorescence imaging, two-
photon imaging, and dynamic histomorphometry. Results CKD animals had significantly higher 
levels of FAM-ZOL accumulation in the proximal tibia, radius and ulna, but not in lumbar vertebral 
body or mandible, based on multiple measurement modalities. Although the majority of trabecular 
bone surfaces were covered with FAM-ZOL in both normal and CKD animals, the latter had 
significantly higher levels of fluorescence per unit bone surface in the proximal tibia. Conclusions 
These results provide a new data regarding how reduced kidney function affects drug 
accumulation in rat bone. 
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INTRODUCTION 
One in  seven individuals within the US is affected by Chronic Kidney Disease (CKD), 60% of 
these showing measurable reductions in kidney function [1]. CKD-mineral bone disorder (CKD-
MBD) is a systemic disorder of altered bone and mineral metabolism that ultimately compromises 
skeletal integrity and increases fracture risk [2-5]. More striking is that rates of mortality associated 
with fractures are considerably elevated in CKD individuals compared to other aged-matched 
patients with fracture  [6]. Developing an approach to reduce fracture risk in this population could 
significantly alter the landscape of health for those with CKD. 
 Despite a basic understanding of the drivers of bone changes in CKD, treatment for the 
skeletal manifestations are limited. The most common class of anti-remodeling agent, 
bisphosphonates, are an effective method to increase bone mass and reduce fracture risk in a 
multitude of metabolic bone diseases including osteoporosis [7, 8]. The current clinical 
recommendations by the Kidney Disease Improving Global Outcomes (KDIGO) describe 
bisphosphonates as an acceptable treatment method in early stage kidney disease (Stage 1-3); 
but discourage use in CKD patients with biochemical evidence of CKD-MBD such as secondary 
hyperparathyroidism typically correlated to later stage CKD (Stage 3-5) [9, 10]. The concern is 
that some of the bisphosphonates (zoledronate and pamidronate) have been shown to cause 
nephrotoxicity in some instances (e.g., high peak concentrations, rapid infusion rate)  [11, 12]. 
Altered kidney function has also been documented in select animal studies [13, 14].  In addition 
to documented nephrotoxicity, there is a theoretical concern that the drug will accumulate in the 
skeleton to levels above those that occur in individuals with normal kidney function [15-18]. This 
latter concern exists because of the absence of data describing skeletal accumulation of 
bisphosphonate in the setting of altered kidney function [19]. Therefore, the goal of this study was 
to utilize an animal model of CKD to test the hypothesis that skeletal accumulation of a 
fluorescently-labelled bisphosphonate (zoledronate) derivative is altered in the setting of reduced 
kidney function.  
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METHODS 
Animals 
The Cy/+ Han:SPRD male rat (hereafter referred to as CKD) provides a well-characterized animal 
model that shows evidence of CKD-MBD by 20-25 weeks of age (~ 50% of normal kidney function 
and significant elevations in parathyroid hormone) and all clinical CKD-MBD manifestations by 35 
weeks of age (~ 10-15% normal kidney function) [20-25]. All procedures conducted in this study 
were reviewed and approved by the Indiana University School of Medicine Institutional Animal 
Care and Use Committee. 
 
Experimental Design 
At 10 weeks of age animals from an in-house breeding colony were identified as normal (NL; n=6) 
or CKD (n=12) based on blood urea nitrogen (BUN) measures (> 30mg/dL at 10 weeks 
designated as CKD). Starting at 24-weeks of age animals were fed a casein-based diet (Harlan 
Teklad TD.04539) which has been shown to produce a more homogeneous development model 
of CKD by raising phosphorus availability [25]. At 25-weeks of age, normal animals (NL, n=6) and 
the one half of CKD animals (n=6) were administered a single subcutaneous injection of 
zoledronic acid conjugated with 5-carboxyfluorescein (FAM-ZOL; 180 μg/kg). This FAM-ZOL 
compound has previously been administered to rats and shown to allow assessment of bone 
surface-binding [26]. Unlike other fluorescent bisphosphonates [27], FAM-ZOL at this dose has 
also been shown to have in vivo biological efficacy as determined by measures of BV/TV in an 
ovariectomy model [26]. An additional group of CKD animals (n=6) was not administered FAM-
ZOL and served as a negative control for fluorescence imaging. 
 All animals were administered calcein via subcutaneous injection (30mg/kg) thirteen and 
six days before the end of the study, allowing assessment of dynamic bone formation. Calcein 
blue (Sigma, #M1255), rather than a more traditional calcein green, was chosen to eliminate 
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spectral overlap with FAM-ZOL [28]. Calcein was mixed to a solution of 0.9% NaCl and 2% 
NaHCO3 at a concentration of 3%; once mixed the solution was buffered to a pH of 7.4 and then 
filtered through a 0.2mm sterile filter.  Approximately 24 hours post-FAM-ZOL dosing animals 
were anaesthetized with isoflurane and underwent a brief non-survival surgery within the chest 
cavity (unrelated to the results presented here) before euthanasia by exsanguination. Long bones 
were harvested from the right limbs (radius, ulna, tibia), while the right hemi-mandible and the L3 
vertebra were also collected. All samples were fixed in NBF (for 24 hours) and then switched to 
70% EtOH and stored at room temperature with the exception of L3 which was stored in 70% 
EtOH the entire time. Bones were stored in amber vials to minimize fluorescence bleaching prior 
to analysis. 
 
Biochemistries 
Blood (~500 μL) was collected from the tail vein prior to euthanasia using capillary tubes.  Blood 
was spun down to collect plasma (about 200 μL) for analysis of BUN (BioAssay systems #DIUR-
100), calcium (Pointe Scientific, #C7503-480), and phosphorus (Pointe Scientific, #P7516-500) 
using colorimetric assays.  
 
Bulk fluorescence imaging 
Whole bone fluorescence assessment was conducted on proximal tibia, mandible, radius, ulna, 
and L3 vertebrae using reflectance epi-fluorescence imaging (IVIS Spectral CT, PerkinElmer). 
Epi-fluorescence imaging of fluorescently-tagged bisphosphonates has been used previously as 
an assay of skeletal uptake [26, 29, 30].  The mandible, radius and ulna were all scanned whole. 
L3 vertebra had the all processes removed leaving just the vertebral body.  Proximal tibiae were 
cut to standard lengths of 10 mm measured from the proximal end of the tibia using a high-speed 
rotary tool with a diamond-tipped blade (Dremel). Individual scans included a bone from each 
animal (e.g. ulna from all 18 animals) were run on a single plate to assure uniform scan settings. 
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Due to the larger size of the mandibles, they were scanned with a (24.4 x 24.4 cm) field of view. 
All other bone sites were scanned using a 13.8 x 13.8 cm field of view. Due to these differences 
in field size comparison of mandible data to other sites was not undertaken. 
 Exposure time per sample plate (comprising of bones from all animals at a given skeletal 
site) was ~ 1 second using broad emission spectra to enable spectral unmixing through an 
excitation and emission series combination ranging from 430 – 465 and 500 – 540 
respectively.  The image series were spectrally unmixed to distinguish the pure FAM-ZOL signal 
from auto fluorescence and calcein blue signals using standard manufacturer software (Living 
Image). The imaging system applies two types of corrections for fluorescent imaging:  1) a flat 
field correction which eliminates pixel-to-pixel sensitivity variations of the detector and distortions 
in the optical path; and 2) outcome variable is computed as radiant efficiency which eliminates 
spatial variations in the excitation source across the image by computing the ratio of the emission 
image to the calibrated excitation image.  Calibration of the excitation source is performed daily 
by the instrument. An average radiant efficiency value ([photons/second]/[µW/cm2]) was 
quantified and is reported for each bone.  
 
Histology 
L3, proximal tibia, and tibia diaphyses were infiltrated and embedded in methyl methacrylate as 
previously described in our laboratory [31]. L3 and proximal tibia were sectioned in the 
parasagittal plane with a rotary microtome for assessment of trabecular bone; tibia diaphyses 
were cut in cross-section using a wire saw for assessment of cortical bone. A non-fluorescent 
mounting medium (Eukitt; Kindler, Freiburg, Germany) was used to cover slip all slides. 
Epi-fluorescence microscopy 
Sections were imaged on a microscope (Leica DM2700) with an arc lamplight source and 
quantified using semiautomatic analysis software (Bioquant). Trabecular bone surfaces covered 
by FAM-ZOL in a region of interest (ROI) of approximately 8 mm2,  located ~0.5 mm distal to the 
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proximal tibia or cranial L3 growth plates, were measured and normalized to total bone surface. 
The ROI was drawn to exclude the area directly adjacent to the cortical shell (~0.5mm away from 
each cortex). Two separate slides were analyzed and the results combined to get percent FAM-
ZOL labelled surface value for each animal. 
Two-photon microscopy 
The fluorescent intensity of FAM-ZOL at individual bone surfaces was assessed by 2-photon 
microscopy using a Leica TCS SP8 system (Leica Microsystems, Germany) equipped with a 
mode-locked Ti:Sapphire laser (MaiTai HP DS,  Newport Spectra-Physics) tuned to 
740nm.  Images (12bit) were collected using three NDD detectors (PMT/blue channel- BP 460/50, 
HyD1/red channel – BP585/40 and HyD2/green channel – BP525/50) and HC PL APO 20x/0.75 
IMM CORR CS2 Oil objective lens. Tile images were collected to cover defined ROI sizes of ~ 
0.9 x 1.3 mm and ~1.3 x 1.75 mm for vertebrae and proximal tibia, respectively. The ROI locations 
were chosen in a similar fashion as in the epi-fluorescence measures described above. Images 
were stitched together using standard software (Fiji) and then the green channel (FAM-ZOL) 
maximum projection was used to create a composite of the highest fluorescence pixels within the 
z-plane for each image. The max projection images were analyzed with a customized MATLAB 
script (Supplementary Figure 1). A manually generated mask image defined bone surface and 
subsequently created an analysis region adjacent to the bone surface to assess pixel intensity. A 
greyscale value above 1600 (on 12-bit images with a greyscale range of 0 - 4095) was chosen to 
define FAM-ZOL label. This threshold was calculated by assessing greyscale values for samples 
absent of FAM-ZOL (CKD without FAM-ZOL) to differentiate bone auto fluorescence from FAM-
ZOL. The average greyscale of labeled pixels was calculated as a measure of the concentration 
of FAM-ZOL within each pixel.  
 Calcein blue label within the image ROI collected by 2-photon microscopy was analyzed 
to determine dynamic histomorphometry measures using standard software (Bioquant). Mineral 
apposition rate (MAR), mineralizing surface (MS/BS,%) calculated by ((0.5*single label) + double 
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label)/total bone surface), and surface-based bone formation rate (BFR/BS, µm3/µm2/year) 
calculations were made using standard methods [32, 33].  
 
Statistics 
All analyses were run using Prism GraphPad software. Data was compared using one-way 
ANOVA with Tukey post-hoc analysis when appropriate or with t-tests (when two groups were 
compared). A priori α-levels were set at 0.05 to determine statistical significance. 
 
RESULTS 
Endpoint serum biochemistries revealed BUN values in both CKD groups were significantly higher 
compared to NL animals with no difference between the two CKD groups (Supplementary Table 
1). Neither serum calcium nor serum phosphorus were significantly different among groups 
(Supplementary Table 1).  
 There was a statistically significant overall difference in bulk tissue radiant efficiency 
(fluorescence intensity) between CKD and NL groups for radius, ulna, and proximal tibia (Table 
1, Figure 1) while there was no significant difference in the L3 or mandible (Table 1, Figure 1). 
At all three skeletal sites having significant differences, CKD animals had higher radiant efficiency 
compared to NL.  
 Surface-based quantification using epi-fluorescence microscopy, revealed NL animals 
had approximately 85 - 95% of trabecular surfaces covered with FAM-ZOL in proximal tibia and 
vertebra, respectively (Figure 2). There was no significant difference among groups for trabecular 
surface covered by FAM-ZOL in the vertebra (Figure 2). CKD animals also had significantly 
higher surface coverage on the periosteal surface of the tibial diaphysis (Table 2). 
Two-photon max projection mosaic scans were used to determine FAM-ZOL fluorescence 
intensity. Proximal tibia trabecular bone FAM-ZOL label intensity was significantly higher in CKD 
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animals compared with NL (p=0.043) (Figure 3). A similar trend was noted in the vertebra 
although differences did not reach statistical significance.  
 Dynamic histomorphometric measures in proximal tibia showed no significant difference 
between groups for MAR, MS/BS, or BFR (Table 3). 
DISCUSSION 
This study was designed to characterize how alterations in kidney function affect the distribution 
and accumulation of a single dose of fluorescently-tagged zoledronate (FAM-ZOL). Our results 
document that animals with CKD (having about 50% of normal kidney function) accumulate 
significantly higher amounts of FAM-ZOL in the proximal tibia, radius, and ulna, but not L3 or the 
mandible, as assessed 24 hours after a single dose. In both normal and CKD animals, the majority 
of trabecular bone surfaces were covered with FAM-ZOL. The higher accumulation in CKD 
animals was driven by greater amounts of FAM-ZOL bound at a given surface, rather than having 
more surfaces bound with compound relative to normal.  
 In animals with normal kidney function, bisphosphonate bind with high affinity to 
hydroxyapatite. Most binding occurs within the first 6 hours [34]. Any drug not bound in the 
skeleton is excreted, unmetabolized by the kidney [2]. Based on this knowledge, we chose to 
examine the skeletal accumulation of FAM-ZOL 24-hours post dose. Our normal animals showed 
between 80 and 100% of trabecular surfaces in the tibia and vertebra were labelled with FAM-
ZOL. This data is in contrast to some of the earliest work examining alendronate localization which 
showed that only a fraction of bone surfaces were labelled – with particular attention drawn to 
resorption surfaces [35]. This latter study is prominently cited in the literature to support the idea 
that bisphosphonate binding is preferential to active surfaces [36-38]. Recent work, although not 
quantifying amount of surface label, suggest robust surface labeling by fluorescent-risedronate 
consistent more in line with the current work [39, 40]. There are a number of potential reasons for 
these discrepancies across studies. The difference in type of bisphosphonate (alendronate versus 
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zoledronate) and method of assessment could both explain differences from our current work, 
although another possible explanation is the age of the animals (earlier work used eight-day old 
animals while the current work used skeletally mature animals). Our results from cortical bone 
were less clear, with periosteal surfaces showing 50-90% coverage and endocortical surfaces 
showing 20-40%.  
 Given the majority of trabecular surfaces were covered with FAM-ZOL in the normal 
animals, we hypothesized that higher bulk levels of accumulation in animals with reduced kidney 
function were due to greater accumulation at given sites. Indeed, using 2-photon microscopy we 
measured average fluorescence on surfaces within a defined region of interest in the proximal 
tibia trabecular bone. This assay revealed significantly greater average fluorescence, suggestive 
of a greater amount of FAM-ZOL on the surface, in animals with CKD (Figure 3). Previous work 
with fluorescent-tagged risedronate and alendronate have analyzed accumulation depth [39, 40], 
where the compound penetrates beyond the exposed surface into the matrix via canaliculi forming 
a band of variable thickness at surfaces. Similar depth measures were not conducted in this work. 
Our results show that FAM-ZOL accumulation on a given surface, rather than accumulation over 
a greater length of surface, is the main difference in trabecular bone between normal and CKD 
conditions. 
 Bisphosphonates are highly effective at reducing fracture risk [7, 8]. Dosing instructions 
for zoledronic acid recommend reduced dosing in patients with creatinine clearance <60 ml/min, 
and ‘use not recommended’ in patients with creatinine clearance <30 ml/min. This is based on 
the idea that transient high circulating levels of drug have been linked to nephrotoxicity.  Yet there 
also exists a theoretical concern that reduced drug clearance, due to reduced kidney function, 
could lead to higher accumulation in the skeleton beyond what would occur in someone with 
normal renal function. The focus of the current study is on the latter. Our data suggest similar 
bone surface coverage, but more accumulation at a given skeletal site in the setting of moderate 
kidney impairment. Although these data provide some insight into the kinetics of skeletal 
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accumulation in animals with compromised kidney function, there is no direct in vivo evidence 
that this higher accumulation has a physiological consequence. In vitro studies illustrate the 
potential for negative effects of bisphosphonate accumulation, with low concentrations of 
numerous bisphosphonates having beneficial effects on osteocyte viability while higher 
concentrations can induce cell death [41, 42]. There exists no evidence that similar accumulation-
based effects exist for remodeling suppression. Future studies that not only quantify levels of 
accumulation but also effects on physiological outcomes (remodeling and/or bone mechanical 
properties) will be essential to paint a more complete picture. 
 CKD can manifest with wide range of bone turnover rates [4, 43] and whether high or low 
remodeling rates exist can affect various properties of the bone. The Cy/+ used in the current 
work has been shown to be a high-remodeling rate model [23], driven by the hyperparathyroidism 
[44] that begins to manifests at least by 20 weeks of age and progressively worsens [24, 25]. The 
current work, for the first time assessed bone remodeling rates in this model at 25 weeks of age, 
finding non-significant differences between CKD and normal animals (Table 3). The most likely 
reason for this finding is not that the effect is not manifesting, but rather that the sample size 
(which was powered for looking at FAM-ZOL) was insufficient for dynamic histomorphometry 
(increasing sample size to n=12/group would raise the power from its current 40% to 73%). Future 
work to determine if higher rates of remodeling (such as occur in advanced disease in this and 
other models) affect binding are warranted.   
 The execution of our study had some limitations. First, the analysis focused on an analog 
of only one bisphosphonate, zoledronate. With the longest half-life and known stable binding 
affinity to bone [45, 46], zoledronate seemed to be a logical one to test for distribution and 
accumulation studies. Nevertheless, each bisphosphate possesses different characteristics and 
varying properties meaning that the results found here cannot be generalize to other 
bisphosphonates. Subcutaneous (SC) administration of drug was used in the current study while 
intravenous (IV) administration is used in patients. Based on a small pilot study, we found SC and 
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IV dosing results in comparable levels of FAM-ZOL in normal animals  (Supplementary Figure 
2). It is also important to note that the addition of a bulky fluorescent tag on zoledronate has the 
potential to affect its binding characteristics and localization and thus it is not possible to 
definitively know that it behaves similar to the native compound. Additionally, this study focuses 
on the distribution and accumulation of FAM-ZOL at a single time point, 24 hours post dose. 
Therefore, the results should not be extrapolated to shorter or longer time frames.  
 In conclusion we have shown that the binding at 24 hours of fluorescently-tagged 
zoledronate differ in the context of reduced kidney function. In both normal and CKD animals the 
fluorescently-tagged zoledronate covered the majority of bone surfaces, yet in the setting of early 
stage CKD there is greater accumulation at a given surface in some, but not all bones.  
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Figure Legends 
Figure 1: Fold difference in bulk fluorescence (average radiant efficiency) of CKD animals relative 
to normal animals across multiple bones assessed.   * p < 0.05 versus normal animals based on 
t-test analysis of absolute values. 
  
Figure 2. Surface based FAM-ZOL coverage of trabecular bone in the proximal tibia (A) and 
vertebra (B) from epi-fluorescence microscopy analysis. Graph data is presented as the mean 
and standard deviation along with individual data points. * p < 0.05. 
 
Figure 3. Two-photon assessment of FAM-ZOL intensity at trabecular bone surfaces of the 
proximal tibia (A) and vertebra (B). Average pixel intensity of CKD animals was significantly higher 
than normal (NL) for the proximal tibia but not the vertebra. Graph data is presented as the mean 
and standard deviation of greyscale values (12-bit images with a greyscale range of 0 - 4095)  
along with individual data points. (C) shows representative proximal tibia images for NL and CKD. 
The left panel displays the original FAM-ZOL images captured on the two-photon microscope and 
then the right panel displayed the thresholded FAM-ZOL signal that was quantified. * p < 0.05. 
 
Supplementary Figure 1. Analysis of two photon images. A) Raw image of green channel 
detector. B) MATLAB Input image with bone area as white and black for bone marrow. C) Analysis 
region with non-analyzed regions shown in grayscale. D) Pixels above FAM-ZOL threshold. 
  
Supplementary Figure 2.  Bulk fluorescence assessment of whole radius and tibia from normal 
animals administered FAM-ZOL by either intravenous (IV) or subcutaneous (SC) injection (n=4 
per dose route).  There was no significant difference in the mean group values between the two 
routes for either the radius or tibia sites (p > 0.60).  
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TABLE 1. Bulk fluorescence total radiant efficiency (fluorescence intensity, [photons/s]/[µW/cm2]) 
 NL – FAM-ZOL CKD – FAM-ZOL CKD as a % 
of NL 
T-test 
Proximal tibia 7.23 x 109 ± 
2.31 x 109 
10.94 x 109 ± 
1.73 x 109 
+ 51% 0.0102 
Radius 9.13 x 109 ±  
5.32 x 109 
21.13 x 109 ±  
6.67 x 109 
+ 131% 0.0057 
Ulna 18.6 x 109 ±  
7.95 x 109 
38.0 x 109 ±  
13.4 x 109 
+ 104% 0.0125 
L3 3.04 x 109 ± 
1.46 x 109 
 
3.85 x 109 ± 
1.74 x 109 
 
- 0.4071 
Mandible 23.7 x 109 ± 
29.1 x 109  
 
64.9 x 109 ± 
45.2 x 109 
 
- 0.0889 
All data presented as mean and standard deviation. µW, micro watts.  
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TABLE 2. Tibia cortical bone FAM-ZOL surface label  
 NL – FAM-ZOL CKD – FAM-ZOL T-test 
Tibial periosteal surface 
FAM-ZOL coverage, % 
55.39 ± 
8.60 
 
88.22 ± 
11.76 
 
0.0003 
Tibial endocortical surface 
FAM-ZOL coverage, % 
17.19 ± 
12.45 
 
38.93 ± 
20.49 
 
0.0505 
 
All data presented as mean and standard deviation. 
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TABLE 3. Dynamic histomorphometry of proximal tibia trabecular bone  
 NL – FAM-
ZOL 
CKD – FAM-
ZOL 
T-test 
Mineral apposition rate, µm/day 
 
1.55 + 
0.40 
 
1.86 + 
0.19 
0.133 
Mineralizing surface/bone surface, % 
18.83 + 
8.65 
 
26.52 + 
4.09 
 
0.077 
Bone formation rate, µm3/µm2/year 113 + 
82 
 
178 + 
33 
 
0.099 
 
All data presented as mean and standard deviation. 
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SUPPLEMENTAL TABLE 1. Serum biochemistries 
 NL – 
FAM-ZOL 
CKD CKD – 
FAM-ZOL 
ANOVA 
BUN (mg/dL) 21.96 ± 
2.61 
 
 
41.01 ± 
4.44 * 
 
 
39.61 ± 
4.38 * 
 
 
< 0.001 
Calcium (mg/dL) 7.77 ± 
1.22 
 
7.43 ± 
1.22 
 
8.44 ± 
1.12 
 
0.3493 
Phosphorus (mg/dL) 5.87 ± 
0.62 
 
6.18 ± 
0.64 
 
6.19 ± 
1.03 
 
0.7300 
All data presented as mean and standard deviation. * p < 0.05 versus NL-FAM-ZOL. 
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